Home > DARE Reviews > Rituximab in lymphoma
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews.

Rituximab in lymphoma

Review published: 2003.

Bibliographic details: Imrie K, Esmail R, Buckstein R, Berinstein N, Meyer R, Hematology Disease Site Group.  Rituximab in lymphoma. This paper is produced by Cancer Care Ontario Practice Guidelines Initiative. The series is published on the Internet and regularly updated. To ensure that you are viewing the most up to date version, go to the Cancer Care Ontario website at: http://www.cancercare.on.ca/english/toolbox/qualityguidelines/pebc/ This abstract is based on the web version accessed on 01/08/2004.

Quality assessment

This well-conducted review found that rituximab is generally well tolerated and may improve response in people with low-grade lymphoma. There were insufficient data on long-term outcomes or people with histological subtypes other than low-grade lymphoma. CHOP chemotherapy plus rituximab appears to improve response and survival more than CHOP alone in people with diffuse large B cell lymphoma. Full critical summary

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2014 University of York.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...